HRP20171641T1 - Genetički polimorfizam kod makularne degeneracije vezane uz dob - Google Patents
Genetički polimorfizam kod makularne degeneracije vezane uz dob Download PDFInfo
- Publication number
- HRP20171641T1 HRP20171641T1 HRP20171641TT HRP20171641T HRP20171641T1 HR P20171641 T1 HRP20171641 T1 HR P20171641T1 HR P20171641T T HRP20171641T T HR P20171641TT HR P20171641 T HRP20171641 T HR P20171641T HR P20171641 T1 HRP20171641 T1 HR P20171641T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- patient
- vegf antibody
- corresponding genotype
- variable domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (10)
1. Postupak predviđanja, da li bi pacijent s vlažnim AMD imao povećanu mogućnost poboljšanja stanja pomoću liječenja s protutijelom velikog afiniteta anti-VEGF, naznačen time, da obuhvaća screening jednog uzorka koji je izoliran iz navedenog pacijenta za genomski poliformizam u alelu gena metaloproteaze matriksa 25 (MMP25), koji odgovara za rs1064875, pri čemu pacijent ima povećanu mogućnost poboljšanja stanja nakon takvog liječenja, ukoliko odgovarajući genotip obuhvaća AA ili AG.
2. Postupak predviđanja, da li bi pacijent s vlažnim AMD imao povećanu mogućnost poboljšanja stanja pomoću liječenja s protutijelom velikog afiniteta anti-VEGF, naznačen time, da obuhvaća screening jednog uzorka koji je izoliran iz navedenog pacijenta za genomski poliformizam u alelu bazalnog transkripcijskog faktora leukin-zatvarača(zipper) (BATF), tipa ATF, koji odgovara za rs175714, pri čemu pacijent ima povećanu mogućnost poboljšanja stanja nakon takvog liječenja, ukoliko odgovarajući genotip obuhvaća AA ili AG.
3. Postupak prema bilo kojem od zahtjeva 1 ili 2, naznačen ime, da navedeno protutijelo anti-VEGF veže isti epitop kao i monoklonalno anti-VEGF-protutijelo A4.6.1 koje je proizvedeno pomoću hibridoma ATCC® HB 10709.
4. Postupak prema zahtjevu 3, naznačen time da navedeno protutijelo anti-VEGF ima varijabilnu domenu jakog lanca koja obuhvaća sljedeće aminokiselinske sekvence od komplementarnog područja određivanja (CDR) jakog lanca: CDRH1 (GYDFTHYGMN; SEQ ID NO:1), CDRH2 (WINTYTGEPTYAADFKR; SEQ ID NO:2) i CDRH3 (YPYYYGTSHWYFDV; SEQ ID NO:3) i varijabilnu domenu slabog lanca koja obuhvaća sljedeće aminokiselinske sekvence od CDR-a slabog lanca: CDRL1 (SASQDISNYLN; SEQ ID NO:4), CDRL2 (FTSSLHS: SEQ ID NO:5) i CDRL3 (QQYSTVPWT; SEQ ID NO:6).
5. Postupak prema zahtjevu 4, naznačen time, da navedeno protutijelo anti-VEGF obuhvaća varijabilnu domenu jakog lanca i varijabilnu domenu slabog lanca od Y0317.
6. Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time, da navedeno protutijelo anti-VEGF je ranibizumab.
7. Postupak prema zahtjevu 1, naznačen time, da odgovarajući genotip obuhvaća AA.
8. Postupak prema zahtjevu 1, naznačen time, da odgovarajući genotip obuhvaća AG.
9. Postupak prema zahtjevu 2, naznačen time, da odgovarajući genotip obuhvaća AA.
10. Postupak prema zahtjevu 2, naznačen time, da odgovarajući genotip obuhvaća AG.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25375809P | 2009-10-21 | 2009-10-21 | |
| PCT/US2010/053334 WO2011050034A1 (en) | 2009-10-21 | 2010-10-20 | Genetic polymorphisms in age-related macular degeneration |
| EP10768847.5A EP2491134B1 (en) | 2009-10-21 | 2010-10-20 | Genetic polymorphisms in age-related macular degeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20171641T1 true HRP20171641T1 (hr) | 2017-12-01 |
| HRP20171641T2 HRP20171641T2 (hr) | 2024-06-07 |
Family
ID=43087069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171641TT HRP20171641T2 (hr) | 2009-10-21 | 2010-10-20 | Genetički polimorfizam kod makularne degeneracije vezane uz dob |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20110159608A1 (hr) |
| EP (1) | EP2491134B1 (hr) |
| JP (1) | JP5676623B2 (hr) |
| KR (1) | KR101566064B1 (hr) |
| CN (1) | CN102686743B (hr) |
| AU (1) | AU2010310804B2 (hr) |
| BR (1) | BR112012009408B1 (hr) |
| CA (2) | CA2859193C (hr) |
| DK (1) | DK2491134T3 (hr) |
| HR (1) | HRP20171641T2 (hr) |
| HU (1) | HUE037152T2 (hr) |
| IL (2) | IL218912A (hr) |
| LT (1) | LT2491134T (hr) |
| MX (2) | MX2012004306A (hr) |
| MY (1) | MY176035A (hr) |
| NO (1) | NO2491134T3 (hr) |
| NZ (1) | NZ599110A (hr) |
| RU (2) | RU2546008C2 (hr) |
| SI (1) | SI2491134T1 (hr) |
| WO (1) | WO2011050034A1 (hr) |
| ZA (1) | ZA201202420B (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140004105A1 (en) * | 2012-06-29 | 2014-01-02 | Sequenom, Inc. | Age-related macular degeneration diagnostics |
| CA3077539C (en) * | 2012-12-27 | 2023-09-12 | Quest Diagnostics Investments Incorporated | Ddr2 mutations as targetable features of melanoma or basal cell carcinoma |
| US20140274749A1 (en) * | 2013-03-15 | 2014-09-18 | Affymetrix, Inc. | Systems and Methods for SNP Characterization and Identifying off Target Variants |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2016090590A1 (en) * | 2014-12-11 | 2016-06-16 | Bayer Healthcare Llc | Treatment of age related macular degeneration with a small active choroidalneovascularizationlesion |
| WO2017096031A1 (en) | 2015-12-03 | 2017-06-08 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US4998617A (en) | 1986-09-15 | 1991-03-12 | Laura Lupton Inc | Facial cosmetic liquid make up kit |
| US6270961B1 (en) | 1987-04-01 | 2001-08-07 | Hyseq, Inc. | Methods and apparatus for DNA sequencing and DNA identification |
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5952172A (en) | 1993-12-10 | 1999-09-14 | California Institute Of Technology | Nucleic acid mediated electron transfer |
| US5968740A (en) | 1995-07-24 | 1999-10-19 | Affymetrix, Inc. | Method of Identifying a Base in a Nucleic Acid |
| KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| WO1999013108A1 (en) | 1997-09-10 | 1999-03-18 | University Of Maryland, Baltimore | Method of amplifying dna and rna mismatch cleavage products |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
-
2010
- 2010-10-20 MX MX2012004306A patent/MX2012004306A/es active IP Right Grant
- 2010-10-20 DK DK10768847.5T patent/DK2491134T3/en active
- 2010-10-20 SI SI201031555T patent/SI2491134T1/sl unknown
- 2010-10-20 NO NO10768847A patent/NO2491134T3/no unknown
- 2010-10-20 NZ NZ599110A patent/NZ599110A/xx not_active IP Right Cessation
- 2010-10-20 US US12/908,290 patent/US20110159608A1/en not_active Abandoned
- 2010-10-20 CA CA2859193A patent/CA2859193C/en active Active
- 2010-10-20 CN CN201080056334.0A patent/CN102686743B/zh not_active Expired - Fee Related
- 2010-10-20 JP JP2012535329A patent/JP5676623B2/ja not_active Expired - Fee Related
- 2010-10-20 CA CA2777928A patent/CA2777928C/en active Active
- 2010-10-20 WO PCT/US2010/053334 patent/WO2011050034A1/en not_active Ceased
- 2010-10-20 MY MYPI2012001759A patent/MY176035A/en unknown
- 2010-10-20 EP EP10768847.5A patent/EP2491134B1/en active Active
- 2010-10-20 AU AU2010310804A patent/AU2010310804B2/en not_active Ceased
- 2010-10-20 RU RU2012120663/15A patent/RU2546008C2/ru active
- 2010-10-20 HU HUE10768847A patent/HUE037152T2/hu unknown
- 2010-10-20 MX MX2015011134A patent/MX367621B/es unknown
- 2010-10-20 LT LTEP10768847.5T patent/LT2491134T/lt unknown
- 2010-10-20 RU RU2015101034/15A patent/RU2577726C2/ru active
- 2010-10-20 BR BR112012009408-4A patent/BR112012009408B1/pt not_active IP Right Cessation
- 2010-10-20 HR HRP20171641TT patent/HRP20171641T2/hr unknown
- 2010-10-20 KR KR1020127012875A patent/KR101566064B1/ko not_active Expired - Fee Related
-
2012
- 2012-03-28 IL IL218912A patent/IL218912A/en active IP Right Grant
- 2012-04-03 ZA ZA2012/02420A patent/ZA201202420B/en unknown
-
2016
- 2016-08-07 IL IL247144A patent/IL247144A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171641T1 (hr) | Genetički polimorfizam kod makularne degeneracije vezane uz dob | |
| JP2018521638A5 (hr) | ||
| JP2012507988A5 (hr) | ||
| JP2016516400A5 (hr) | ||
| JP2011173884A5 (hr) | ||
| JP2018535670A5 (hr) | ||
| HRP20160584T1 (hr) | Novo anti-dr5 antitijelo | |
| JP2014512809A5 (hr) | ||
| CA2818635C (en) | Antibodies selective for cells presenting erbb2 at high density | |
| JP2020517249A5 (hr) | ||
| JP2020500538A5 (hr) | ||
| HRP20140049T1 (hr) | Anti beta-amiloid antitijela i njihova upotreba | |
| JP2020535799A5 (hr) | ||
| RU2017114341A (ru) | Антитела к pd-l1, связывающие pd-l1 собаки | |
| JP2021501744A5 (hr) | ||
| FI3390451T3 (fi) | Kaninisoidut ihmisen vasta-aineet ihmisen ja koiraeläimen il-4r alfaa kohtaan | |
| JP2016063812A5 (hr) | ||
| JP2019536806A5 (hr) | ||
| IL273196B1 (en) | Claudin 6 antibodies and methods of cancer treatment | |
| IL296682B2 (en) | Method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists | |
| JP2017522892A5 (hr) | ||
| JP2015028021A5 (hr) | ||
| JP2010533495A5 (hr) | ||
| JP2011527899A5 (hr) | ||
| FI3310812T3 (fi) | Anti-her2-vasta-aineita ja käyttömenetelmiä |